These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 19168203)

  • 41. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer.
    Jani AB; Feinstein JM; Pasciak R; Krengel S; Weichselbaum RR
    Urology; 2006 May; 67(5):1007-11. PubMed ID: 16635512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
    Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    Cancer J Sci Am; 1998; 4(6):359-63. PubMed ID: 9853134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
    BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
    Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
    J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
    Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
    J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
    Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
    McMullen KP; deGuzman AF; McCullough DL; Lee WR
    Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
    Rossi PJ; Clark PE; Papagikos MA; McCullough DL; Lee WR
    Urology; 2006 Feb; 67(2):349-53. PubMed ID: 16461084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.